Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
BLACKROCK INC BLK |
4,032,876 7.500% |
-1,542,440 (-27.67%) |
Filing History |
| 2025-02-12 09:32 am Purchase |
2024-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
Adage Capital Management L.P. | 3,000,000 5.560% |
3,000,000 (New Position) |
Filing History |
| 2025-01-06 4:50 pm Purchase |
2024-12-27 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 3,404,612 6.300% |
2,221,821 (+187.85%) |
Filing History |
| 2024-12-06 4:28 pm Sale |
2024-11-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
BLACKROCK INC BLK |
5,575,316 10.300% |
-131,304 (-2.30%) |
Filing History |
| 2024-11-14 4:53 pm Purchase |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
Nantahala Capital Management, LLC | 4,777,912 7.657% |
4,777,912 (New Position) |
Filing History |
| 2024-11-14 4:25 pm Sale |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,182,791 2.200% |
-4,336,090 (-78.57%) |
Filing History |
| 2024-11-14 06:15 am Sale |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
RTW Investments, LP | 0 0.000% |
-5,469,956 (Position Closed) |
Filing History |
| 2024-11-12 3:51 pm Unchanged |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
The Vanguard Group | 3,274,592 5.240% |
0 (Unchanged) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
BLACKROCK INC BLK |
5,706,620 9.100% |
0 (Unchanged) |
Filing History |
| 2024-11-04 11:49 am Purchase |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
The Vanguard Group | 3,274,592 5.240% |
3,274,592 (New Position) |
Filing History |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
BLACKROCK INC BLK |
5,706,620 9.100% |
4,192,195 (+276.82%) |
Filing History |
| 2024-10-07 11:37 am Sale |
2024-10-04 | 13G | Fulcrum Therapeutics, Inc. FULC |
FMR CORP | 1,724,014 2.762% |
-3,960,601 (-69.67%) |
Filing History |
| 2024-09-20 4:21 pm Purchase |
2024-09-12 | 13G | Fulcrum Therapeutics, Inc. FULC |
TCG Crossover GP II, LLC | 5,000,000 9.400% |
5,000,000 (New Position) |
Filing History |
| 2024-09-16 8:21 pm Purchase |
2024-09-12 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 10,229,099 19.300% |
4,684,883 (+84.50%) |
Filing History |
| 2024-08-23 4:16 pm Sale |
2024-08-21 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 5,544,216 9.990% |
-6,065,488 (-52.24%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
RA Capital Management, L.P. | 11,609,704 18.800% |
1,923,076 (+19.85%) |
Filing History |
| 2024-02-14 4:19 pm Unchanged |
2023-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
Third Rock Ventures III L.P. | 2,343,154 3.800% |
0 (Unchanged) |
Filing History |
| 2024-02-14 07:53 am Purchase |
2023-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
RTW Investments, LP | 5,469,956 8.800% |
476,677 (+9.55%) |
Filing History |
| 2024-02-13 12:08 pm Purchase |
2023-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,518,881 8.900% |
1,244,078 (+29.10%) |
Filing History |
| 2024-02-09 09:03 am Purchase |
2024-02-08 | 13G | Fulcrum Therapeutics, Inc. FULC |
FMR CORP | 5,684,615 9.195% |
450,890 (+8.62%) |
Filing History |